Back to search results

Study of Buprenorphine Treatment for Opioid Use Disorder in Jail

This study is looking at the best way to give buprenorphine to men with Opioid Use Disorder (OUD) who are in jail. It compares two forms of buprenorphine: Extended-Release Buprenorphine (XRB), given as a monthly injection, and Sublingual Buprenorphine (SLB), which is taken under the tongue. You could join if you are an incarcerated man, unsentenced, already taking SLB, and expect to be in jail for at least 4 days. The study wants to see if XRB helps more people leave jail with enough buprenorphine in their system, continue treatment after release, and reduce misuse of buprenorphine. The study is currently unclear on its recruitment status.

Study design
This is a randomized controlled trial involving 200 participants. Participants will be randomly assigned to receive either XRB or continue with SLB.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured up to Month 6 after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06051890

Assessing Optimal XRB Initiation Points in Jail

Recruiting
PHASE4All AgesInterventionalTreatment
NYU Langone Health
~50 participants
Updated 2026-08-07 on ClinicalTrials.gov
What's tested:Extended-Release Buprenorphine (XRB)Sublingual Buprenorphine (SLB)

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of participants released from jail with at least 7 days of buprenorphine in their system
Measured over Up to Month 6

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

4 sites across 3 states
Massachusetts2
New Jersey1
New York1

Study leadership

  • David Farabee, PhD · PRINCIPAL_INVESTIGATOR · NYU Langone Health

Who to contact

David Farabee
[email protected]
310-963-0009
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Incarcerated men able to provide written informed consent in English.\*
Unsentenced.
Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days.
Minimum anticipated jail stay is 4 days.
Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated).

Exclusion

Sentenced.
Allergy, hypersensitivity or medical contraindication to either medication.
Chronic pain requiring opioid pain management or other contraindicated medications.

What this trial measures

  • Percentage of participants released from jail with at least 7 days of buprenorphine in their systemUp to Month 6

    The percentage of participants leaving jail with at least 7 days of buprenorphine protection in their system. Measured using clinical and jail records.